Course: Optimizing Treatment With Infusion-Based Therapies for HR+/HER2- and Triple-Negative Breast Cancer
Released: 0000-00-00
Program Description
Click to Go to the Event Registration
The treatment landscape for metastatic HR+/HER2- and triple-negative breast cancer (TNBC) is rapidly evolving with the emergence of novel infusion-based therapies, including antibody-drug conjugates and targeted therapies.
Join this live, virtual symposium following the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference 2024 to learn about cutting-edge strategies that will enable pharmacists to optimize use of these novel therapies. Learn from experts as they discuss current challenges, emerging trial data, adverse event mitigation, dose modifications, and strategies to support coordinated, equitable, evidence-based, and guideline-aligned treatment and management of breast cancer.
Combine this knowledge with a concise point-of-care resource to equip you with evidence-based best practices and recommendations for administering infusion therapies and managing adverse events in patients with HR+/HER2- and triple-negative breast cancer.
Agenda
I. Challenges in the Treatment and Management of Metastatic Breast Cancer
Role of Novel Agents, Including Antibody-Drug Conjugates in the Treatment of Metastatic HR+/HER2- Breast Cancer and TNBC
II. Examining the Latest Clinical Evidence on Novel Therapies for Metastatic HR+/HER2- Breast Cancer and TNBC
III. Guideline Recommendations for Dosing, Managing, and Monitoring Novel Therapies in Metastatic Breast Cancer
Avoiding Drug-Drug Interactions
Mitigating Adverse Events
Introduction of the Infusion Therapy Resource: Optimizing Treatment for Metastatic HR+/HER2- Breast Cancer & TNBC
IV. Expert Strategies for Coordinating Care Between Pharmacists and Oncology Teams to Support Equitable, Evidence-Based Treatment and Management
Intended Audience
Oncology pharmacy practitioners who care for patients with mBC, including HR+/HER2- and TNBC
Commercial Supporter
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Learning Objectives
Upon completion of this activity, learners should be able to:
Assess the role of novel therapies for the treatment of metastatic breast cancer, including antibody-drug conjugates approved for metastatic HR+/HER2- breast cancer and/or TNBC
Apply the latest clinical practice guidelines into treatment algorithms or institutional protocols for patients with metastatic HR+/HER2- breast cancer and/or TNBC
Integrate strategies for monitoring and managing adverse events related to novel metastatic breast cancer therapies that consider drug-drug interactions, toxicity management, dose reduction, and supportive care
Design effective strategies to overcome disparities in the access and delivery of care for patients with metastatic breast cancer
Employ evidence-based approaches to coordinate treatment and management of patients with metastatic breast cancer between pharmacists and medical oncologists and their clinical teams
View Full Course